Friday January 2, 2026

Biocon Biologics Signs Settlement and License Agreement to

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), announced today a new settlement and license agreement with Regeneronand Bayer for biosimilar Aflibercept (40mg/ml) in Europe and the rest of the world, which follows an earlier settlement covering the UnitedStates and Canada.